Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Alterity Therapeutics Limited
ABN	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Ann Cunningham
Date of last notice	21 April 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)	N/A
Date of change	26 November 2026
No. of securities held prior to change	NIL
Class	UNLISTED OPT EXP 26/11/2031 @ $1.00
Number acquired	500,000 - UNLISTED OPT EXP 26/11/2031 @ $1.00
Number disposed	NIL
Value/Consideration	NIL CONSIDERATION
No. of securities held after change	500,000 - UNLISTED OPT EXP 26/11/2031 @ $1.00
Nature of change	Incentive options

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

+ See chapter 19 for defined terms.

No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Alterity Therapeutics Limited
ABN	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	David Stamler
Date of last notice	02 September 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	(1) Direct (2) Indirect
Nature of indirect interest (including registered holder)	(1) N/A (2) HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED - 139,258 AMERICAN DEPOSITARY SHARES (equivalent to 1,671,096 FULLY PAID ORDINARY SHARES)
Date of change	(1.1) N/A (1.2) N/A (1.3) N/A (1.4) N/A (1.5) 26 November 2026 (2) N/A

+ See chapter 19 for defined terms.

No. of securities held prior to change	(1.1) 233,767 - FULLY PAID ORDINARY SHARES (1.2) 30,304 - LISTED OPT EXP 26/02/2027 @ $1.40 (1.3) 800,004 - UNLISTED OPT EXP 21/03/2029 @ US$0.15 (1.4) 5,808,000 - UNLISTED OPT EXP 08/08/2030 @ US$0.43 (1.5) NIL - UNLISTED OPT EXP 26/11/2031 @ $1.00 (2) 139,258 - AMERICAN DEPOSITARY SHARES (equivalent to 1,671,096 FULLY PAID ORDINARY SHARES)
Class	(1.1) FULLY PAID ORDINARY SHARES (1.2) LISTED OPT EXP 26/02/2027 @ $1.40 (1.3) UNLISTED OPT EXP 21/03/2029 @ US$0.15 (1.4) UNLISTED OPT EXP 08/08/2030 @ US$0.43 (1.5) UNLISTED OPT EXP 26/11/2031 @ $1.00 (2) AMERICAN DEPOSITARY SHARES (one ADS equivalent to 12 FULLY PAID ORDINARY SHARES)
Number acquired	(1.1) NIL (1.2) NIL (1.3) NIL (1.4) NIL (1.5) 3,700,008 - UNLISTED OPT EXP 26/11/2031 @ $1.00 (2) NIL
Number disposed	(1.1) NIL (1.2) NIL (1.3) NIL (1.4) NIL (1.5) NIL (2) NIL
Value/Consideration	(1.1) N/A (1.2) N/A (1.3) N/A (1.4) N/A (1.5) NIL CONSIDERATION (2) N/A

No. of securities held after change	(1.1) 233,767 - FULLY PAID ORDINARY SHARES (1.2) 30,304 - LISTED OPT EXP 26/02/2027 @ $1.40 (1.3) 800,004 - UNLISTED OPT EXP 21/03/2029 @ US$0.15 (1.4) 5,808,000 - UNLISTED OPT EXP 08/08/2030 @ US$0.43 (1.5) 3,700,008 - UNLISTED OPT EXP 26/11/2031 @ $1.00 (2) 139,258 - AMERICAN DEPOSITARY SHARES (equivalent to 1,671,096 FULLY PAID ORDINARY SHARES)
Nature of change	(1.1) N/A (1.2) N/A (1.3) N/A (1.4) N/A (1.5) Options issued pursuant to the Employee Securities Incentive Plan (2) N/A

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Alterity Therapeutics Limited
ABN	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Julian Barbaczy
Date of last notice	17 June 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder)	Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C> - Director
Date of change	(1.1) N/A (1.2) 26 November 2026
No. of securities held prior to change	(1.1) 2,000,000 - UNLISTED OPT EXP 15/06/2031 @ $1.00 (1.2) NIL - UNLISTED OPT EXP 26/11/2031 @ $1.00
Class	(1.1) UNLISTED OPT EXP 15/06/2031 @ $1.00 (1.2) UNLISTED OPT EXP 26/11/2031 @ $1.00
Number acquired	(1.1) NIL (1.2) 500,000 - UNLISTED OPT EXP 26/11/2031 @ $1.00
Number disposed	(1.1) NIL (1.2) NIL
Value/Consideration	(1.1) N/A (1.2) NIL CONSIDERATION
No. of securities held after change	(1.1) 2,000,000 - UNLISTED OPT EXP 15/06/2031 @ $1.00 (1.2) 500,000 - UNLISTED OPT EXP 26/11/2031 @ $1.00

+ See chapter 19 for defined terms.

Nature of change	(1.1) N/A (1.2) Incentive options

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Alterity Therapeutics Limited
ABN	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Lawrence Gozlan
Date of last notice	17 June 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	(1) Indirect
Nature of indirect interest (including registered holder)	(1) Montoya Pty Ltd <Buttercup A/C> - Director
Date of change	(1.1) N/A (1.2) N/A (1.3) N/A (1.4) N/A (1.5) 26 November 2026
No. of securities held prior to change	(1.1) 1,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.50 (1.2) 1,000,000 - UNLISTED OPT EXP 15/06/2031 @ $1.00 (1.3) 90,910 - FULLY PAID ORDINARY SHARES (1.4) 30,304 - LISTED OPT EXP 26/02/2027 @ $1.40 (1.5) NIL - UNLISTED OPT EXP 26/11/2031 @ $1.00
Class	(1.1) UNLISTED OPT EXP 30/12/2027 @ $0.50 (1.2) UNLISTED OPT EXP 15/06/2031 @ $1.00 (1.3) FULLY PAID ORDINARY SHARES (1.4) LISTED OPT EXP 26/02/2027 @ $1.40 (1.5) UNLISTED OPT EXP 26/11/2031 @ $1.00

+ See chapter 19 for defined terms.

Number acquired	(1.1) NIL (1.2) NIL (1.3) NIL (1.4) NIL (1.5) 500,000 - UNLISTED OPT EXP 26/11/2031 @ $1.00
Number disposed	(1.1) NIL (1.2) NIL (1.3) NIL (1.4) NIL (1.5) NIL
Value/Consideration	(1.1) N/A (1.2) N/A (1.3) N/A (1.4) N/A (1.5) NIL CONSIDERATION
No. of securities held after change	(1.1) 1,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.50 (1.2) 1,000,000 - UNLISTED OPT EXP 15/06/2031 @ $1.00 (1.3) 90,910 - FULLY PAID ORDINARY SHARES (1.4) 30,304 - LISTED OPT EXP 26/02/2027 @ $1.40 (1.5) 500,000 - UNLISTED OPT EXP 26/11/2031 @ $1.00
Nature of change	(1.1) N/A (1.2) N/A (1.3) N/A (1.4) N/A (1.5) Incentive options

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A

+ See chapter 19 for defined terms.

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Alterity Therapeutics Limited
ABN	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Peter Marks
Date of last notice	02 September 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	(1) Indirect - Lampam Pty Ltd (2) Direct (3) Indirect - Shanti Capital Pty Ltd <Peter Marks Super Fund A/C>
Nature of indirect interest (including registered holder)	(1) Director (2) N/A (3) Super fund
Date of change	(1) N/A (2) 26 November 2026 (3.1) N/A (3.2) N/A (3.3) 26 November 2026 (3.4) 26 November 2026

+ See chapter 19 for defined terms.

No. of securities held prior to change	(1) 191,340 - FULLY PAID ORDINARY SHARES (2) 600,000 - UNLISTED OPT EXP 30/12/2027 @ $0.50 (3.1) 36,364 - FULLY PAID ORDINARY SHARES (3.2) 12,122 - LISTED OPT EXP 26/02/2027 @ $1.40 (3.3) NIL - UNLISTED OPT EXP 30/12/2027 @ $0.50 (3.4) NIL - UNLISTED OPT EXP 26/11/2031 @ $1.00
Class	(1) FULLY PAID ORDINARY SHARES (2) UNLISTED OPT EXP 30/12/2027 @ $0.50 (3.1) FULLY PAID ORDINARY SHARES (3.2) LISTED OPT EXP 26/02/2027 @ $1.40 (3.3) UNLISTED OPT EXP 30/12/2027 @ $0.50 (3.4) UNLISTED OPT EXP 26/11/2031 @ $1.00
Number acquired	(1) NIL (2) NIL (3.1) NIL (3.2) NIL (3.3) 600,000 - UNLISTED OPT EXP 30/12/2027 @ $0.50 (3.4) 500,000 - UNLISTED OPT EXP 26/11/2031 @ $1.00
Number disposed	(1) NIL (2) (600,000 - UNLISTED OPT EXP 30/12/2027 @ $0.50) (3.1) NIL (3.2) NIL (3.3) NIL (3.4) NIL
Value/Consideration	(1) N/A (2) NIL CONSIDERATION (3.1) N/A (3.2) N/A (3.3) NIL CONSIDERATION (3.4) NIL CONSIDERATION

No. of securities held after change	(1) 191,340 - FULLY PAID ORDINARY SHARES (2) NIL - UNLISTED OPT EXP 30/12/2027 @ $0.50 (3.1) 36,364 - FULLY PAID ORDINARY SHARES (3.2) 12,122 - LISTED OPT EXP 26/02/2027 @ $1.40 (3.3) 600,000 - UNLISTED OPT EXP 30/12/2027 @ $0.50 (3.4) 500,000 - UNLISTED OPT EXP 26/11/2031 @ $1.00
Nature of change	(1) N/A (2) Off-Market Transfer (3.1) N/A (3.2) N/A (3.3) Off-Market Transfer (3.4) Incentive Options

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.